新冠檢測概念板塊走強 我國將大規模開展核酸和抗體檢測
格隆匯4月23日丨新冠檢測概念板塊走強,明德生物、邁克生物、達安基因等集體漲停,科創板碩世生物大漲超12%,華大基因、安迪診斷等跟漲。

中央應對新冠肺炎疫情工作領導小組22日召開會議。會議指出,做到“四早”首要是早發現。做好常態化防控要加快提升檢測能力,大規模開展核酸和抗體檢測。要加快提升檢測技術,抓緊增加更簡便、更高效準確的檢測設備生產,廣泛配備到醫院、口岸等急需方面,擴大商業化應用,做到對重點人羣應檢盡檢,對復工復產中人員聚集的單位、場所優先做到願檢盡檢。
21日,阿里巴巴旗下阿里健康宣佈,聯合美年健康和迪安健檢天貓旗艦店,首期在10個城市推出在線預約新冠核酸檢測服務,本週內將陸續覆蓋38座城市。迪安診斷集團客服中心負責人22日表示,諮詢的增量超出預期,“昨晚接待時間一直延到凌晨後”,客服人均接待諮詢超300人次。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.